2-amino-1-phenyl-3-methylbutane | 46114-16-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-amino-1-phenyl-3-methylbutane
• 英文别名: 3-Methyl-1-phenylbutan-2-ylamine；3-methyl-1-phenylbutan-2-amine；1-Benzyl-2-methylpropylamin；2-amino-3-methyl-1-phenylbutane；2-Amino-3-methyl-1-phenyl-butan；3-Amino-2-methyl-4-phenyl-butan；1-Phenyl-2-amino-3-methylbutane
• CAS: 46114-16-3
• 化学式: C₁₁H₁₇N
• 分子量: 163.263
• InChiKey: AKXXBEHEYPLJPX-UHFFFAOYSA-N

物化性质

• 沸点：
  120 °C(Press: 20 Torr)
• 密度：
  0.926±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-amino-1-phenyl-3-methylbutane 在 PPA 、 硫酸 、 硼烷 、 potassium carbonate 、 potassium nitrate 作用下， 以 四氢呋喃 为溶剂， 反应 5.25h， 生成 3-Isopropyl-7-nitro-1,2,3,4-tetrahydroisoquinoline
  参考文献：
  名称：

  Exploring the active site of phenylethanolamine N-methyltransferase: 3-alkyl-7-substituted-1,2,3,4-tetrahydroisoquinoline inhibitors

  摘要：

  A series of 3 -alkyl-7 -substituted-1,2,3,4-tetrahydroisoquinolines was synthesized and these compounds were evaluated for their PNMT inhibitory potency and affinity for the (alpha(2)-adrenoceptor. 7-Nitro-, 7-bromo-, 7-aminosulfonyl-, or 7-N-2,2,2-trifluoroethylaminosulfonyl-THIQs that possess a 3-alkyl substituent that is longer than a methyl group showed decreased PNMT inhibitory potency, except for 3-propyl-7-aminosulfonyl-THIQ, which displayed excellent PNMT inhibitory potency. The rank order for selectivity (PNMT vs the alpha(2)-adrenoceptor) is 3 -alkyl -7 -aminosulfonyl-THIQs congruent to 3-alkyl-7-N-2,2,2-trifluoroethylaminosulfonyl-THIQs > 3-alkyl-7-nitro-THlQs > 3-alkyl-7-bromo-THIQs. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2004.11.015
• 作为产物：
  描述：

  3-Methyl-1-phenyl-N-[(R)-1-phenylbutoxy]butan-2-ylamine 在 水 、 溶剂黄146 、 锌 作用下， 生成 2-amino-1-phenyl-3-methylbutane
  参考文献：
  名称：

  Chiral oxime ethers in asymmetric synthesis. Part 4. Asymmetric synthesis of N-protected amines and β-amino acids by the addition of organometallic reagents to ROPHy/SOPHy-derived aldoximes

  摘要：

  将有机锂或格氏试剂添加到（R）或（S）-O-(1-苯基丁基)醛肟1，在三氟化硼–二乙醚的存在下，形成具有良好到优异的二烯选择性的羟胺2。随后使用锌–醋酸–超声波 cleavage N–O 键，并形成氨基甲酸酯，得到N保护的胺3，具有良好的对映体纯度（77–100% ee）。当使用烯丙基溴化镁作为有机金属试剂时，得到的羟胺被转化为β-氨基酸衍生物4和γ-氨基醇5。

  DOI：

  10.1039/a907186e

文献信息

• Rapid, one-pot synthesis of α,α-disubstituted primary amines by the addition of Grignard reagents to nitriles under microwave heating conditions
  作者：Brian T. Gregg、Kathryn C. Golden、John F. Quinn、Hong-Jun Wang、Wei Zhang、Ruifang Wang、Francis Wekesa、Dmytro O. Tymoshenko

  DOI：10.1016/j.tetlet.2009.04.081

  日期：2009.7

  A series of α,α-disubstituted amines have been prepared in a simple and efficient one-pot procedure by the addition of Grignard reagents to a series of aliphatic, aromatic, and heteroaromatic nitriles. Key to this reported procedure is the unprecedented addition of the Grignard reagent to the nitrile under heating by microwave irradiation which both significantly improves reaction yields and reduces

  通过将格氏试剂添加到一系列脂族，芳族和杂芳族腈中，以简单有效的一锅法制备了一系列α，α-二取代胺。该报道方法的关键是在微波辐射加热下，将格氏试剂前所未有地添加到腈中，这既显着提高了反应产率，又缩短了反应时间。通常，格利雅（Grignard）加成反应在100°C下5-10分钟内完成，然后用硼氢化钠快速还原，得到目标胺。
• Nucleotide and oligonucleotide prodrugs
  申请人：Iyer P. Radhakrishnan

  公开号：US20070149462A1

  公开（公告）日：2007-06-28

  The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

  本发明揭示了具有以下式（I）的化合物：这些化合物具有抗病毒性能。本发明还涉及包含上述化合物的药物组合物，用于给需要抗乙型肝炎治疗的受试者使用。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
• An efficient and enantioselective synthesis of a chiral primary amine
  作者：Youngchan Son、Chihyo Park、Jong Sung Koh、Nakyen Choy、Chang S. Lee、Ho-il Choi、Sung Chun Kim、Heungsik Yoon

  DOI：10.1016/s0040-4039(00)73087-5

  日期：1994.5

  An efficient and enantioselective method for the preparation of a chiral primary amine has been developed. Starting from N-protected L or D-amino acid the sequence involves coupling with N-methoxy-N-methylamine, acylation, olefination with potassium bis(trimethylsilyl)amide, and hydrogenation.

  已经开发了制备手性伯胺的有效和对映选择性的方法。从N-保护的L或D-氨基酸开始，该序列包括与N-甲氧基-N-甲胺偶联，酰化，与双（三甲基甲硅烷基）酰胺钾的烯化以及氢化。
• [EN] AMINOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'AMINOPYRIDINE
  申请人：VANTIA LTD

  公开号：WO2009133348A1

  公开（公告）日：2009-11-05

  The present invention provides compounds of formula (I): compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R1 - R11 are as defined herein.

  本发明提供了式（I）的化合物：包含这些化合物的组合物；在治疗中使用这些化合物（例如哮喘或COPD）；以及使用这些化合物治疗患者的方法；其中R1 - R11如本文所定义。
• Irreversible HIV protease inhibitors, compositions containing same and process for the preparation thereof
  申请人：LG Chemical Limited

  公开号：EP0812839A1

  公开（公告）日：1997-12-17

  The present invention relates to novel compounds of formula (I) which has inhibitory activities against human immunodeficiency virus ("HIV") protease, a process for the preparation thereof, and compositions for prevention or treatment of AIDS by HIV infection comprising the above compounds as active ingredients. wherein: R1 is an aromatic group, a nitrogen-containing aromatic group, C1-4 alkyl group optionally substituted with an aromatic group or a nitrogen-containing aromatic group, C1-4 alkoxy group optionally substituted with an aromatic group or a nitrogen-containing aromatic group; R2 is an amino acid residue or a C1-8 alkyl group substituted with a C1-4 alkylsulfonyl group; R3 is a C1-4 alkyl group optionally substituted with an aromatic group; R4 is hydrogen or a C1-2 alkyl group; R5 is a C1-10 alkyl group optionally substituted with an aromatic group; and n is 1 or 2.

  本发明涉及具有对人类免疫缺陷病毒（“HIV”）蛋白酶具有抑制活性的化合物的新型化合物（I）的公式，以及其制备方法，以及包括上述化合物作为活性成分的用于预防或治疗HIV感染引起的艾滋病的组合物。其中：R1是芳香基，含氮芳香基，C1-4烷基，可选地取代为芳香基或含氮芳香基的C1-4烷基，或可选地取代为芳香基或含氮芳香基的C1-4烷氧基；R2是氨基酸残基或取代为C1-4烷基磺酰基的C1-8烷基；R3是可选地取代为芳香基的C1-4烷基；R4是氢或C1-2烷基；R5是可选地取代为芳香基的C1-10烷基；n为1或2。